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Abstract
Background: Biodistribution studies based on organ harvesting represent the gold standard pre-clinical technique
for dose extrapolations. However, sequential imaging is becoming increasingly popular as it allows the extraction of
longitudinal data from single animals, and a direct correlation with deterministic radiation effects. We assessed the
feasibility of mouse-specific, microPET-based dosimetry of an antibody fragment labeled with the positron emitter
152Tb [(T1/2 = 17.5 h, Eβ+mean = 1140 keV (20.3%)]. Image-based absorbed dose estimates were compared with
those obtained from the extrapolation to 152Tb of a classical biodistribution experiment using the same antibody
fragment labeled with 111In.
152Tb was produced by proton-induced spallation in a tantalum target, followed by mass separation and cation
exchange chromatography. The endosialin-targeting scFv78-Fc fusion protein was conjugated with the chelator
p-SCN-Bn-CHX-A”-DTPA, followed by labeling with either 152Tb or 111In. Micro-PET images of four immunodeficient
female mice bearing RD-ES tumor xenografts were acquired 4, 24, and 48 h after the i.v. injection of 152Tb-CHX-
DTPA-scFv78-Fc. After count/activity camera calibration, time-integrated activity coefficients (TIACs) were obtained
for the following compartments: heart, lungs, liver, kidneys, intestines, tumor, and whole body, manually segmented
on CT. For comparison, radiation dose estimates of 152Tb-CHX-DTPA-scFv78-Fc were extrapolated from mice
dissected 4, 24, 48, and 96 h after the injection of 111In-CHX-DTPA-scFv78-Fc (3–5 mice per group). Imaging-derived
and biodistribution-derived organ TIACs were used as input in the 25 g mouse model of OLINDA/EXM® 2.0, after
appropriate mass rescaling. Tumor absorbed doses were obtained using the OLINDA2 sphere model. Finally, the
relative percent difference (RD%) between absorbed doses obtained from imaging and biodistribution were
calculated.
Results: RD% between microPET-based dosimetry and biodistribution-based dose extrapolations were + 12, − 14,
and + 17 for the liver, the kidneys, and the tumors, respectively. Compared to biodistribution, the imaging method
significantly overestimates the absorbed doses to the heart and the lungs (+ 89 and + 117% dose difference,
respectively).
Conclusions: MicroPET-based dosimetry of 152Tb is feasible, and the comparison with organ harvesting resulted in
acceptable dose discrepancies for body districts that can be segmented on CT. These encouraging results warrant
additional validation using radiolabeled biomolecules with a different biodistribution pattern.
Keywords: microPET, Small animal dosimetry, 152Tb, OLINDA/EXM® 2.0, Biodistribution, Organ harvesting, TEM-1,
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Introduction
The assessment of radiotracer biodistribution in preclin-
ical animal models is an essential part of radiopharma-
ceutical drug development. The standard method for
obtaining biodistribution data has long been the ex vivo
measurement of radioactivity concentration in organs of
small mammals, dissected at given time points after ra-
diopharmaceutical administration. In addition, there is a
growing interest in generating radiation dosimetry data
from preclinical studies, in order to better define the
radiobiological implications of novel probes, with par-
ticular regard to the toxicity and efficacy profiles of
therapeutic radiopharmaceuticals [1, 2]. According to
the RADAR formalism [3], two terms are required for
the calculation of the absorbed dose to a target tissue:
the dose factors (DFs) and the time-integrated activity.
The DFs incorporate information on the physical prop-
erties of the radionuclide, on the geometrical interplay
between source and target organs, as well as on their
structure. Thanks to the development of realistic small
animal geometric phantoms and their implementation in
commercial dosimetry software, an accurate calculation
of DFs for small animals is now easily accessible [4–6].
The time-integrated radiotracer activity in a given
tissue can be estimated either by classical biodistribution
studies, or by sequential single-photon (microSPECT) or
positron-emission tomographic (microPET) imaging. Im-
aging techniques are to be preferred in the long term as
they allow for longitudinal studies, thereby reducing the
number of animals needed for the experiments.
Previous studies have assessed the correlation between
in vivo small animal imaging and ex vivo counting for the
measurement of activity concentration in single organs
using conventional radionuclides such as 18F, 99mTc, or
111In [7–9]. However, to obtain radiation dose estimates,
organ uptake needs to be assessed over time, and organ
volumes calculated individually, due to inter- and
intra-species heterogeneity. Studies validating mouse-
specific, imaging-based dosimetry against radiation dose
extrapolations obtained from biodistribution experiments
are missing.
The present work was carried out to assess the feasi-
bility of mouse-specific, microPET-based dosimetry of
an antibody fragment labeled with the unconventional
positron emitter 152Tb. Image-based absorbed dose esti-
mates were compared with dosimetry results obtained
from the extrapolation to 152Tb of a classical biodistri-




152Tb is a β+ emitter (average β+ energy: 1140 keV, 20.3%
branching ratio, 17.5 h half-life), which was produced by
proton-induced spallation in a tantalum target, followed
by an online isotope separation process at ISOLDE
(CERN, Geneva, Switzerland) as previously reported
[10–12]. Mass 152 ions were implanted into zinc-coated
gold foils, and 152Tb was then purified at the Paul Scher-
rer Institute (PSI, Villigen-PSI, Switzerland) using a
macroporous strongly acidic cation exchange chromato-
graphic resin (Sykam Vertriebs GmbH, Germany) and
eluting the product using α-hydroxyisobutyric acid (α-
HIBA; pH 4.7, 0.11M) [13, 14]. The final product was
used directly for labeling purposes.
Radiolabeling with 152Tb and 111In
The scFv78-Fc fusion protein targeting endosialin/tumor
endothelial marker 1 (TEM1) was obtained as previously
described [15] and conjugated with 10 eq. of the chelator
p-SCN-Bn-CHX-A”-DTPA (Macrocyclics, cat. no. B-355)
at 42 °C and pH 9.1 (full details will be reported else-
where). The final solution was diluted in 0.9% NaCl to
give a concentration of 5 mg/mL CHX-DTPA-scFv78-Fc.
A solution of 15MBq of 152Tb in 90 μL α-HIBA was
added to 20 μL of CHX-DTPA-scFv78-Fc dissolved in
100 μL of NH4OAc buffer (pH 5.4, 0.4M). After 1 h
incubation at 42 °C, 152Tb-CHX-DTPA-scFv78-Fc was
obtained without further purification with a purity > 95%
(iTLC, citrate buffer pH 4.6).
For biodistribution experiments, a commercially avail-
able 111In chloride solution (200MBq Mallinckrodt) was
added to a mixture of NH4OAc buffer (pH 5.4, 0.4 M,
100 μL) and CHX-DTPA-scFv78-Fc (50 μL). After 1 h
incubation at 42 °C, an 80–90% conversion was obtained
(iTLC, citrate buffer pH 4.6). The product was diluted
with 0.9% NaCl and purified by ultrafiltration.
MicroPET imaging of 152Tb-CHX-DTPA-scFv78-Fc
All animal experiments in the present study were con-
ducted according to the Swiss federal law on animal ex-
perimentation under the authorization number VD-2993.
TEM-1 expressing Ewing Sarcoma cells (RD-ES, DSMZ,
Germany, no. ACC 260) were cultured and grafted subcuta-
neously in 8–12-weeks-old common gamma KO Balb/c
female mice (3 × 106 cells injected in the right flank) weigh-
ing about 25 g. Ten-minute images (Energy window 358–
664 keV) of 4 RD-ES tumor-bearing mice were acquired on
a small animal PET/SPECT/CT device (Albira, Brucker)
[16], at three time-points (4, 24, and 48 h) after the intraven-
ous injection of 5–10MBq 152Tb-CHX-DTPA-scFv78-Fc
(25–30 μg of total antibody per mouse).
Mice were anesthetized using isoflurane (2% in 1 L/min
medical air) and warmed on a heating pad during the scan.
Images were reconstructed using a three-dimensional
maximum likelihood expectation maximization algorithm
with 12 iterations, without any post-reconstruction
smoothing. The PET in-plane FOV size was 80 mm
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with axial extension of 149mm; reconstructed image
voxel size was 0.5 mm isotropic in space. Dead-time, scat-
ter, and random corrections were applied. Co-registered
CT (0.2mA, 35 kV) were used for anatomical localization
of uptake and attenuation correction.
Camera calibration
152Tb was quantified and checked for radionuclidic purity
using a calibrated N-type high-purity germanium coaxial
detector (Eurisys Mesures, Montigny Le Bretonneux,
France) in conjunction with a multi-channel analyzer
(ORTEC DSPEC Jr., Oak Ridge, TN, USA) and the appro-
priate spectroscopy software system (Interwinner, Itech
Instruments, Rognac, France).
A NEMA-NU4 micro-PET image quality phantom
(main volume = 20mL) was filled with a known activity of
8.2MBq 152Tb in an aqueous solution resulting in an ac-
tual activity concentration (Ac,bg) of 410 kBq/mL (Fig. 1).
For phantom imaging and reconstruction, we adopted the
same camera settings described above for animal imaging.
Quantitative imaging data were obtained by multiplying
the measured signal by the scaling factor: SF = (Sbg/
Ac,bg)
−1, where Sbg is the average signal measured in
the phantom background region.
MicroPET-based dosimetry
Volumes of interest (VOI) were obtained by manual
segmentation of axial CT slices of each micro-PET/
CT acquisition using the polygonal segmentation tool
available in PMOD (PMOD Technologies, version
3.9, Zurich, Switzerland) for the following regions:
heart, lungs, liver, kidneys, intestines, tumor, and
whole body (Fig. 2).
For each single animal, the total activity measured
in source organs at each time-point was divided by
the total administered activity to obtain the normal-
ized time-activity curves (nTAC). nTAC were fitted
by a mono-exponential function extended to infinite
beyond the last measured data point. Time-integrated
activity coefficients (TIACs, in units of MBq·h/MBq)
were obtained from analytical integration of the
mono-exponential fit for each of the source organs.
The TIAC for the rest-of-body was obtained by sub-
tracting the sum of all source organ TIACs from the
whole-body TIAC. In order to obtain the organ
absorbed doses (mGy/MBq), organ TIACs were used
in the input to the OLINDA/EXM® 2.0 (Hermes Med-
ical Solution AB, Stockholm, Sweden, referred as
“OLINDA2” thereafter) mouse model (25 g) [6]. For
organs that could be resolved by CT, organ volumes
were taken from direct segmentation of CT images
acquired 24 h post-injection. Organ masses were cal-
culated by multiplying organ volumes by the standard
tissue densities indicated in the ICRP110 for humans
[17] and used in the input to OLINDA2. This was
made possible thanks to a specific mass-rescaling tool
in order to replace the standard organ masses avail-
able for the mouse model. To estimate the absorbed
dose to the large intestine and the small intestine re-
spectively, the TIAC and the mass calculated by seg-
mentation of the whole intestine were partitioned
proportionally to the masses of the two single compo-
nents available in the murine phantom 25 g (i.e., 75%
small intestine, 25% large intestine). The absorbed
dose to the tumor was obtained using the sphere
model available in OLINDA2. The final radiation
absorbed doses to organs and tumors, along with
their standard deviations, were obtained by averaging
the absorbed doses values estimated in the four
animals.
Results of the OLINDA2 sphere model were compared
with those of an analytical model for determining
absorbed fractions and doses in ellipsoids filled with a
uniform activity concentration [18–20]. To implement
the analytical model, we used the full 152Tb emission
spectrum taken from [21], which includes the β+
spectrum extending up to 2.97MeV, and all monoener-
getic electrons and photons.
The comparison between OLINDA2 and the analytical
model for ellipsoidal shapes was carried out for 8
Fig. 1 NEMA-NU4 phantom filled with a uniform activity of 152Tb, used to derive the count/activity calibration factor
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spheres of masses ranging from 0.1 to 10 g. The com-
parison assumed a TIAC of 1 h and unit-density soft tis-
sue. The relative percent differences between doses
calculated with OLINDA2 and with the ellipsoidal model
were obtained as
ε ¼ 100  DOLINDA2−Dellipsoid
Dellipsoid
Biodistribution studies
Biodistribution of 111In-CHX-DTPA-scFv78-Fc was also
obtained in 8–12-week-old RD-ES tumor-bearing female
common gamma KO Balb/c mice. Mice were injected
intravenously with 150 kBq (range 30–440 kBq) 111In-
CHX-DTPA-scFv78-Fc and sacrificed 4 h (n = 3 mice),
24 h (n = 5 mice), 48 h (n = 4 mice), and 96 h (n = 3
mice) post-injection. Before injection, 25 μg of unlabeled
scFv78-Fc were added to a saline solution containing
0.2 μg of 111In-CHX-DTPA-scFv78-Fc, in order to ad-
minister the same amount of total antibody used for
microPET studies. Mice were bled by cardiac puncture
and sacrificed by cervical dislocation under anesthesia
with isoflurane (2% in 1 L/min medical air). Organs were
excised and weighed, and radioactivity was counted on a
gamma counter (Wallac Wizard, Perkin Elmer, Wal-
tham, MS, USA). For each time point, the activity of
each source organ of each single animal was normalized
by the total injected activity to obtain nA. For each
source organ at each time point, an average nA value
was obtained ±1SD.
Biodistribution-based dosimetry
To allow the comparison with microPET-based dosim-
etry results, radiation dose estimates of 152Tb-CHX-
DTPA-scFv78-Fc were extrapolated from 111In-CHX-
DTPA-scFv78-Fc biodistribution data.
nA values for 152Tb were extrapolated from 111In mea-
sured data points by the application of a scale factor (SF):
SF tmð Þ ¼ exp −In 2ð Þ=Tp;Tb−152
  tm
 
= exp −In 2ð Þ=Tp;In−111
  tm
 
Where tm indicates the measured time points (4, 24,
48, and 96 h post-injection, respectively), therefore,
nATb−152ðtmÞ ¼ nAIn−111ðtmÞ  SFðtmÞ
This rescaling procedure compensates for the different
physical half-life of the two radioisotopes, assuming the
same biological half-life.
The nTAC obtained from all source organs was found to
be monotonically decreasing; therefore, to derive TIACs,
three analytical mono-exponential fits were applied to the
nTACs generated from the average nA, average nA + 1SD,
and average nA–1SD data points, respectively.
Consistently with the image-based dosimetric method-
ology, 152Tb-CHX-DTPA-scFv78-Fc organ absorbed doses
and tumor doses were obtained using the murine (25 g)
model and the sphere model available in OLINDA2,
respectively [6]. The standard organ masses of the
OLINDA2 mouse model 25 g were replaced by the aver-
age organ masses measured across all animals used for the
biodistribution experiments. The relative percent differ-
ence between absorbed doses obtained from microPET
Fig. 2 Example of manual CT-based segmentation of most relevant thoracic (heart, lungs) and abdominal organs (liver, kidneys, and intestines),
along with a subcutaneous tumor on the right flank
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imaging (ADim) and the absorbed doses extrapolated from
biodistribution (ADbiod) was calculated as follows:
RDð%Þ ¼ ½ðADim−ADbiodÞ=ADbiod 100
Results
MicroPET images showed progressive clearance from
the blood pool and increased tumor uptake between 4 h
and 24 h post-injection. Most of the radioactivity was
seen in the liver, with consequent apparent spill-out in
adjacent thoracic and abdominal organs. The last time-
point image showed persistent uptake in the abdomen
and in the tumor, although with inferior image quality due
to radioactive decay (Fig. 3). Complete decay-corrected
pharmacokinetics, as resulted from 111In-CHX-DTPA-
scFv78-Fc biodistribution experiments, is shown in Fig. 4.
In the spleen and the female pelvic organs uterus and
ovary, a constant biological uptake was seen up to 48 h
after tracer injection, followed by washout 96 h post-
injection. In the microPET images, these organs are not
easily identifiable, which represents a limitation of the
imaging method.
With the exception of the kidneys, all organ masses
calculated by CT segmentation were larger than those
calculated by harvesting and direct weighing of organs
of similar-sized animals used for the biodistribution ex-
periments. Specific organ and tumor masses calculated
with the two methods are given in Table 1. Figure 5
shows the TIACs obtained with both modalities for most
relevant compartments. Relative percent dose differences
between microPET-based dosimetry and biodistribution-
based dose extrapolations were + 12, − 14, and + 17 for
the liver, the kidneys, and the tumors, respectively. Com-
pared to extrapolations from biodistribution data, the
imaging method significantly overestimated the absorbed
doses to the heart and the lungs (+ 89 and + 117% dose
difference, respectively). Full dosimetry results are given
in Table 2.
Results of the comparison between absorbed doses cal-
culated with OLINDA2 and with the ellipsoidal model are
reported in Table 3. OLINDA2, and the ellipsoidal model
are in excellent agreement for spheres of masses > 1 g,
where the average relative percent difference is − 2.9%.
For spheres in the mass range 0.1–0.5, the difference
increases to about − 10%.
Discussion
Sequential radionuclide imaging is becoming increasingly
popular in preclinical studies as it allows the extraction of
longitudinal data from single animals. For similar reasons,
when studying dose/response predictions, imaging-based
small animal dosimetry is theoretically advantageous over
biodistribution-based dose extrapolations. In fact, if dos-
imetry data are extrapolated from living animals, the de-
terministic effects of radiation can be directly assessed,
potentially driving a more accurate translation of thera-
peutic radiopharmaceuticals to the clinic. However, ex-
perience with imaging-based methods is still limited, and
their validation against dose extrapolations from classical
biodistribution experiments is necessary.
Bretin et al. compared microPET imaging and organ
harvesting for mouse dosimetry of 6-[18F]fluoro-L-DOPA
and 2-[18F]fluoro-L-tyrosine, showing a good correlation
between the two methods [22]. However, in this study,
the same set of reference organ masses was used, thus,
the information on the inter-subject heterogeneity was
lost and the technical differences between the two
methods for absorbed dose estimations could not be ex-
haustively determined.
Fig. 3 MicroPET longitudinal imaging of 152Tb-CHX-DTPA-scFv78-Fc targeting TEM-1 in a mouse bearing a subcutaneous RD-ES tumor
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Denis-Bacelar et al. compared microSPECT imaging
and organ harvesting for the calculation of %IA/g in sub-
cutaneous tumors after the injection of 111In-labeled mono-
clonal antibodies [23]. They obtained a median %IA/g
difference of about 30% between the two methods, resulting
from discrepancies in the calculation of both tumor masses
and activity concentrations. However, %IA/g was calculated
from single time-points only, rather than from longitudinal
imaging and biodistribution data [23].
In the present study, radiation dosimetry data were ex-
trapolated from microPET sequential imaging of an anti-
body fragment labeled with the radio lanthanide 152Tb
for the first time. This unconventional radionuclide was
produced at the on-line isotope separator ISOLDE, at
CERN, as part of the PSI-ISOLDE collaboration, and
made available to research partners as a basis towards
the frame of an international collaboration [24]. Due to
its 17.5 h half-life, 152Tb appears suitable for imaging
relatively long biological processes and, interestingly, it
can be substituted with other radioisotopes of Tb (e.g.,
149Tb, 155Tb, 161Tb) covering the entire spectrum of the
medical applications of radionuclides [10]. On the other
hand, 152Tb features a highly energetic positron and sev-
eral prompt gamma emissions that may contribute to
image degradation [11].
Our results show the feasibility of 152Tb microPET-
based dosimetry with available hardware and software
technology. In particular, for macroscopic subcutaneous
tumors and organs at risk such as liver and kidneys,
152Tb microPET-based dosimetry compared well with
dose extrapolations obtained from organ harvesting,
with relative differences in the range 12–17%.
Notably, the biodistribution-based dosimetry was based
on four data point (4 h, 24 h, 48 h, and 96 h), whereas the
imaging-based dosimetry was based on three data points
Fig. 4 Biological organ kinetic of the radiolabeled antibody corrected for radioisotope physical decay. For each time point, color bars represent
the average percent of injected activity per gram of tissue (%IA/g) ± 1SD
Table 1 Organ and tumor masses used for dosimetry
calculations. Mean organ and tumor masses obtained by direct
harvesting and weighing, as well as those obtained by PET/CT
imaging segmentation, are shown together with the standard
organ masses implemented in the mouse model 25 g of
OLINDA2. The standard organ masses of OLINDA2 were used
for dose estimations in the organs that were not harvested or
segmented in the biodistribution and microPET experiments,
respectively (indicated with –)
Source organ Average organ masses (g)
Biodistribution MicroPET/CT OLINDA2
Brain – – 0.46
LLI contents 0.76 (± 0.18) 1.19 (± 0.53) 0.58
Small intestine 1.26 (± 0.24) 3.56 (± 1.61) 1.74
Stomach 0.59 (± 0.20) – 0.05
Heart wall 0.10 (± 0.01) 0.19 (± 0.08) 0.23
Kidneys 0.26 (± 0.03) 0.21 (± 0.11) 0.30
Liver 0.97 (± 0.15) 1.18 (± 0.26) 1.73
Lungs 0.17 (± 0.03) 0.24 (± 0.04) 0.08
Pancreas 0.10 (± 0.02) – 0.30
Cortical bone – – 2.18
Spleen 0.04 (± 0.03) – 0.11
Testes – – 0.16
Thyroid – – 0.01
Urinary bladder contents – – 0.06
Tumor 1.05 (± 0.35) 0.79 (± 0.20) N.A.
Uterus and ovary 0.25 (± 0.07) – N.A.†
†A specific organ mass for mouse female reproductive organs is not available
in the mouse model 25 g of OLINDA2
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only (4 h, 24 h, 48 h). This was possible thanks to the longer
half-life of 111In compared to 152Tb, and was functional to
the objective of having a more robust gold standard against
which to compare microPET-based dosimetry with 152Tb.
However, the latest data point (96 h) had little impact on
the extrapolated 152Tb-based organ TIACs. In fact, if the
last measured data point was excluded, all organ 152Tb-
based TIACs would have varied less than 6%, with the ex-
ception of a larger variation of 36% observed for the spleen
(for example, the variation of the tumor TIAC was 4%, full
data not shown). This is because 96 h following the injec-
tion (~ 6 effective half-lives), the remaining 152Tb activity is
very low and gives only a little contribution to the deter-
mination of the TIAC. It may be argued that, for the biodis-
tribution experiments, the use of 152Tb instead of 111In
would have been optimal. However, this was not possible
given the limited availability of 152Tb.
As expected, due to the significant spill-out activity
from the liver in the living animal, image-based dosim-
etry of some organs, typically the lungs, suffers from a
large overestimation compared to the biodistribution
method, where organs are excised and counted separ-
ately. Nevertheless, these considerations might not hold
true for radiopharmaceuticals that do not preferen-
tially distribute in large abdominal organs such as the
liver. The biodistribution pattern shown here is not
due to specific TEM1 expression by the liver [25, 26],
rather it is common to all antibodies bearing a func-
tional Fc region [27].
Other organs, not specifically segmented on CT,
show a general overestimation of the absorbed dose
with the imaging-based method. This can be ex-
plained by the signal spill-out from the source organs
that is consequently added to the remainder of the
body. Radiation dose to the heart was also overesti-
mated by the imaging method, due to its proximity to
the liver and, probably, to the contribution of blood
counts. In general, the presence of circulating blood
might increase the signal in all living organs in PET-
based dosimetry. In contrast, during organ harvesting,
the blood is mostly washed out and does not contrib-
ute to the counting. However, this has probably only
little effect in the present study, limited to the earliest
time point, as the blood clearance of the scFv78-Fc
was rapid (Fig. 4).
A major limitation of the imaging-based technique
is the technical difficulty concerning the segmenta-
tion of small abdominal or pelvic organs. This is due
to the small organ size which often cannot be re-
solved by the low-dose CT co-registered with small
Fig. 5 Normalized time-activity curves (nTAC) obtained for most relevant organs. The organ activity was normalized to the mice administered
activity. Normalized activity time-points derived from PET are labeled with circles, while squares indicate data obtained from biodistribution
experiments. Mean ± SD are reported for each time point. Full lines represent nTAC mono-exponential fits. The goodness of the fits was
expressed by the R2 metric. R2 was > 0.96 for all fits calculated for the liver, lungs, and kidneys. R2 for the biodistribution-derived tumor nTAC fit
was 0.97, whereas R2 for the imaging-derived tumor nTAC fit was 0.67
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animal PET or SPECT. For example, in the present
study, the biodistribution experiments revealed a
prominent uptake in the spleen and in the female
reproductive organs, which could not be translated
into reliable corresponding image-based absorbed
dose estimates because these body districts could not
be adequately contoured on CT.
Another possible limitation of the study is the ab-
sence of partial volume effect (PVE) correction.
Correction for PVE would have required a dedicated
phantom study, which, in any case, could have not
taken into account the signal blurring caused by the
animal respiratory movements. Moreover, in the
presence of organs with high uptake placed in close
proximity, the validity of the application of PVE
correction would have been questionable. On the
other hand, PVE correction might have been useful
for activity quantification in the tumors, which were
far from the most active organs. However, as shown
in Fig. 3, radioactivity was mainly contained within
the tumor margins; therefore, the PVE effect was
deemed minimal in this case.
Given that there are no previously available data on
152Tb dosimetry, we also compared the output of the
spherical model of OLINDA2 with that of an inde-
pendent analytical model for ellipsoidal shapes [17–
19]. The two methods were highly concordant for
masses > 1 g, while differences increased for smaller
masses. The larger discrepancies for smaller masses
could be attributable to the different calculation ap-
proaches for absorbed fractions and doses between
the two methods [28], and might warrant further
investigations.
Table 2 Absorbed dose estimations of 152Tb-CHX-DTPA-scFv78-Fc in mice. The table reports dosimetry results obtained with the
microPET-based method, as compared with the dose extrapolation from 111In-CHX-DTPA-scFv78-Fc biodistribution data. On the
right, the relative percent difference between the two methods is given
Target organ Absorbed doses (mGy/MBq)
microPET-based Biodistribution-based Relative
difference (%)Mean dose Std dev. Mean dose Std dev.
Brain 6.34E + 01 2.84E + 01 3.94E + 01 1.27E + 01 60.98
Large intestine† 3.63E + 02 9.36E + 01 2.34E + 02 6.30E + 01 54.91
Small intestine† 3.45E + 02 8.84E + 01 3.29E + 02 6.00E + 01 4.71
Stomach wall 4.66E + 02 3.43E + 02 1.09E + 02 3.57E + 01 327.75
Heart wall† 6.28E + 02 1.41E + 02 3.31E + 02 7.70E + 01 89.65
Kidneys† 3.32E + 02 5.10E + 01 3.89E + 02 8.40E + 01 − 14.65
Liver† 5.90E + 02 1.27E + 02 5.24E + 02 9.70E + 01 12.60
Lungs† 3.20E + 02 4.58E + 01 1.47E + 02 4.00E + 01 117.86
Pancreas 2.24E + 02 2.56E + 01 3.60E + 02 7.50E + 01 − 37.78
Skeleton 1.11E + 02 2.27E + 01 6.57E + 01 1.81E + 01 68.99
Spleen 9.48E + 01 2.62E + 01 6.92E + 02 1.23E + 02 − 86.30
Testes 6.68E + 01 2.87E + 01 4.10E + 01 1.31E + 01 62.87
Thyroid 7.22E + 01 2.93E + 01 4.39E + 01 1.40E + 01 64.46
Urinary bladder 8.85E + 01 3.01E + 01 5.13E + 01 1.54E + 01 72.56
Total body 1.58E + 02 3.34E + 01 9.99E + 01 2.50E + 01 58.41
Tumor† 2.14E + 02 6.94E + 01 2.60E + 02 7.23E + 01 − 17.66
†Indicates organs that were segmented on microPET/CT imaging, for which the comparison between dose obtained with the two methods appears more
meaningful. As regards dosimetry data to the heart, however, it should be noted that imaging-based data were obtained by manual contouring of both the heart
wall and the heart content (see example of image segmentation in Fig. 2)
Table 3 Dose factors for 152Tb uniformly distributed in spheres
of unit-density tissue, according to OLINDA2 and to the
ellipsoidal model described in [17–19]. Relative percent







difference (%)OLINDA2 Ellipsoidal model
0.1 0.58 6.78E + 02 7.52E + 02 − 9.8
0.5 0.98 1.84E + 02 2.04E + 02 − 9.8
1 1.24 1.11E + 02 1.14E + 02 − 2.6
2 1.56 6.09E + 01 6.25E + 01 − 2.6
4 1.97 3.30E + 01 3.40E + 01 − 2.9
6 2.25 2.30E + 01 2.37E + 01 − 3.0
8 2.48 1.78E + 01 1.84E + 01 − 3.3
10 2.67 1.46E + 01 1.51E + 01 − 3.3
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Conclusion
In this study, we demonstrated that microPET-based
dosimetry of an unconventional radionuclide such as
152Tb is feasible, and the comparison with organ har-
vesting resulted in acceptable dose discrepancies for
body parts that could be segmented on CT. These en-
couraging results warrant additional validation using
radiolabeled molecules with a different biodistribution
pattern.
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